Ascendis Pharma A/S ADR (ASND)

Ascendis Pharma A/S ADR (ASND) is looking forward to a strong quarter – Sete News - SETE News

SETE News

Examining Ascendis Pharma A/S ADR (ASND) stock is warranted – US Post News - US Post News

US Post News

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing

Zacks Investment Research

Ratios Reveal: Breaking Down Ascendis Pharma A/S ADR (ASND)'s Financial Health – DWinneX - The Dwinnex

The Dwinnex

A Tale of Resilience: Ascendis Pharma A/S ADR Amid Stock Market Turbulence - The InvestChronicle

The InvestChronicle

FDA extends review of Ascendis Pharma's hypoparathyroidism drug - Investing.com

Investing.com

Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism

GlobeNewswire Inc.

TransCon PTH shows promise in renal function study - Investing.com

Investing.com

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial

GlobeNewswire Inc.

Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024

GlobeNewswire Inc.

Does Ascendis Pharma A/S ADR (ASND) offer a good opportunity for investors? – Sete News - SETE News

SETE News

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

GlobeNewswire Inc.

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

Zacks Investment Research

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

GlobeNewswire Inc.

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Zacks Investment Research

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Zacks Investment Research

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

Zacks Investment Research

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys - Yahoo Finance

Yahoo Finance

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

Zacks Investment Research

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

GlobeNewswire Inc.

These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher

Benzinga

Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

Zacks Investment Research

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? - Yahoo Finance

Yahoo Finance

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

Zacks Investment Research

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

GlobeNewswire Inc.

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire Inc.

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

Zacks Investment Research

Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024

GlobeNewswire Inc.

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

GlobeNewswire Inc.

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

GlobeNewswire Inc.

Ascendis Pharma Introduces Vision 2030

GlobeNewswire Inc.

Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc.

Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week

GlobeNewswire Inc.

TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

GlobeNewswire Inc.

FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

GlobeNewswire Inc.

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

GlobeNewswire Inc.

Your Guide To 2017's Emerging Pharmaceuticals Catalysts - Sangamo Therapeutics (NASDAQ:SGMO), Lexicon Pha - Benzinga

Benzinga